| View printer-friendly version |
Charles River Laboratories Completes Sale of Clinical Phase II - IV Business
WILMINGTON, Mass.--(BUSINESS WIRE)--Aug. 16, 2006--Charles River Laboratories International, Inc. (NYSE: CRL) today completed the previously announced sale of its Phase II-IV Clinical Services business to Kendle International Inc. The sale of the business was completed in accordance with the terms and conditions of the Stock Purchase Agreement, as amended, between Charles River and Kendle dated as of May 9, 2006.
About Charles River Laboratories
Charles River Laboratories, based in Wilmington, Massachusetts, partners with global pharmaceutical and biotechnology companies to advance the drug discovery and development process, bringing drugs to market faster and more efficiently. Charles River's 7,500 employees serve clients worldwide. For more information on Charles River, visit our website at www.criver.com.
CONTACT: Charles River Laboratories International, Inc.
Investor Contact:
Susan E. Hardy, 781-262-7616
Corporate Vice President, Investor Relations
or
Media Contact:
Elizabeth Ferber, 978-658-6000 Ext.1693
Director, Corporate Communications
SOURCE: Charles River Laboratories International, Inc.